CompaniesHealthcare & FitnessPharmaceuticalsPrint articleBrief: ViralyticsCorporate news snapshot for ViralyticsJan 19, 2010 – 3.22pmSaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this article NewSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? LoginViralytics (VLA) has had success with its Phase I late stage melanoma trial of Cavatak. The primary safety objective of this trial was to assess the safety and tolerability of two doses of Cavatak when injected directly to a single tumour.Loading...SaveLog in or Subscribe to save articleShareCopy linkCopiedEmailLinkedInTwitterFacebookCopy linkCopiedShare via...Gift this article NewSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? LoginLicense articleIntroducing your NewsfeedFollow the topics, people and companies that matter to you.Find out moreRead MorePharmaceuticalsViralytics LimitedLatest In Healthcare & fitnessFetching latest articlesMost Viewed In Companies
